African Journal of Biotechnology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

 

Afr. J. Biotechnol.


Vol. 2 No. 10


Viewing options:


 • Abstract
 • Full text
 •Reprint (PDF) (80K)

Search Pubmed for articles by:


Numazaki K

 


Other links:


PubMed Citation


Related articles in PubMed

 

African Journal of Biotechnology Vol. 2 (10), pp. 392-393, October 2003

ISSN 1684–5315  © 2003 Academic Journals

 


Short Communication

 

Glycyrrhizin therapy for viral infections

 

Kei Numazaki

 

Department of Pediatrics, Sapporo Medical University, School of Medicine, Sapporo, Hokkaido, 060-8543, Japan. Tel: (011) 611-2111 EXT.3413, Fax: (011) 611-0352, E-mail: numazaki@sapmed.ac.jp.

 

Accepted 26 September 2003

 
    Abstract

 

 

 

Glycyrrhizin (GL) was reported as the most active in inhibiting replication of the severe acute respiratory syndrome (SARS)-associated coronavirus. Therapeutic effect of GL for liver dysfunction associated with cytomegalovirus (CMV) infection in immunocompetent individuals was evaluated. Liver dysfunction in 4 cases improved and CMV disappeared from urinary samples after administration of GL intravenously by the age of 12 months. GL treatment also should be applied for the patients with SARS.

 

Key words: Glycyrrhizin, SARS, cytomegalovirus.  

 

 

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Copyright © 2003 by Academic Journals.